-
Berberrubine and Vitamin K Cycle in Thrombosis
2026-08-24
The reference study combines a carrageenan-induced mouse tail thrombosis model, non-targeted metabolomics, and molecular docking to investigate how berberrubine hydrochloride inhibits thrombus formation. Its central contribution is linking the antithrombotic phenotype to changes in vitamin K catalytic-cycle pathways and possible interactions with VKOR and GGCX, while also examining bleeding time and prothrombin time.
-
PRDX6–GPX4 Control of Ferroptosis
2026-08-23
Hu et al. identify PRDX6 as a dual-function regulator of GPX4, combining peroxide-phospholipid hydrolysis with disulfide-dependent GPX4 recruitment to membranes. The study shows that inhibiting PRDX6 can increase ferroptosis and suppress liver and ovarian tumor growth, providing a mechanistic framework for studying resistance to lipid peroxidation-driven cancer therapy.
-
Atorvastatin Workflows for Ferroptosis Research
2026-08-22
Build pathway-informed assays with Atorvastatin, an HMG-CoA reductase inhibitor that connects cholesterol metabolism, vascular signaling, and emerging ferroptosis research. This guide translates recent hepatocellular carcinoma findings into practical cell, migration, and translational workflows with troubleshooting checkpoints.
-
Hexetidine in Comparative Antiseptic Mouthrinse Research
2026-08-22
The 1981 Roberts and Addy study is notable for combining tube-dilution antibacterial testing with protein-interference experiments and a controlled salivary follow-up after a single rinse. Its results show that Hexetidine had the highest MICs among the four cationic antiseptics tested, yet retained measurable salivary antibacterial activity longer than cetyl pyridinium chloride, illustrating why in vitro potency alone does not predict oral performance.
-
Obeticholic Acid: FXR Signaling for Liver Models
2026-08-21
Obeticholic Acid is a selective FXR agonist for investigating bile acid homeostasis, cholestasis, and liver fibrosis biology. This article distinguishes direct FXR evidence from emerging Notch and NK-cell findings to help researchers select more informative assays and models.
-
AMPK Links Mitophagy and Inflammation in Diabetes
2026-08-20
A 2026 FASEB Journal study identifies AMPK as an upstream coordinator of PINK1/Parkin-mediated mitophagy and NLRP3-associated inflammation in periodontal ligament fibroblasts exposed to mechanical loading. Its in vivo and in vitro findings suggest that restoring mitochondrial quality control may be especially important when hyperglycemia intensifies periodontal inflammatory stress.
-
Chloroquine: Mechanism, Evidence, and Research Use
2026-08-20
Chloroquine is a 4-aminoquinoline and autophagy-modulating research compound with applications spanning malaria, rheumatoid arthritis, antiviral, and cancer studies. Its lysosomal effects are mechanistically useful, but in-vitro activity and pathway modulation do not establish clinical efficacy or a safe dose.
-
IgSF6 Deficiency Rewires Intestinal Antibacterial Defense
2026-08-19
The reference study identifies the endoplasmic reticulum-localized immunoglobulin superfamily member IgSF6 as a regulator of stress and inflammatory signaling in intestinal macrophages. Its loss strengthens antibacterial activity through the IRE1α–XBP1 pathway and reactive oxygen species, while also increasing susceptibility to chemically induced colitis, revealing a trade-off between pathogen resistance and tissue homeostasis.
-
DMXAA (Vadimezan): Mechanism-Aware Assay Design
2026-08-19
Explore how DMXAA (Vadimezan) links DT-diaphorase inhibition, VEGFR2 signaling, and tumor vascular injury. This mechanism-aware guide also explains how COPII–STING trafficking research can sharpen assay interpretation without overstating cross-domain evidence.
-
Malate: A Redox Lens on Tumor Metabolism
2026-08-18
Malate is more than a tricarboxylic acid cycle intermediate: it is a practical probe of mitochondrial redox state, metabolic flux, and tumor–immune communication. This article translates recent PDHA1 succinylation findings into assay strategies for interpreting malate-dependent metabolic phenotypes.
-
Arachidonic Acid Supplementation and Humoral Immunity
2026-08-18
The reference study identifies dietary arachidonic acid as a potential nutritional adjuvant that accelerates rabies vaccine-induced neutralizing antibody responses in mice and human volunteers. Its mechanistic contribution is the connection of arachidonic acid enrichment in lymph nodes with prostaglandin I2–cAMP–PKA signaling, CD86 expression, and activation-induced cytidine deaminase activity in B cells.
-
Merbromin: From Fluorescence to Assay Design
2026-08-17
Merbromin is more than a fluorescent dye: it is a versatile platform for connecting molecular binding, pharmaceutical measurement, and inhibition assay design. This guide translates published spectroscopic findings into practical decisions for selecting readouts, controls, and applications.
-
Fluo-4 AM Calcium Assay Kit for Mechanotransduction
2026-08-17
Use the Fluo-4 AM Calcium Assay Kit to convert scaffold-induced Ca2+ dynamics into a live-cell readout for annulus fibrosus mechanobiology. Its 488 nm-compatible, no-wash workflow also supports scalable GPCR inhibitor screening and GPCR agonist screening while preserving cells for downstream phenotype analysis.
-
APEX2 Enables Efficient TERT Expression in Stem Cells
2026-08-16
This preprint identifies APEX2, but not its paralog APEX1, as a regulator required for efficient TERT expression in human embryonic stem cells and a melanoma model. By combining APEX2 knockdown, telomerase assays, RNA sequencing, and chromatin immunoprecipitation, the study links DNA repair at repetitive intronic elements with transcriptional control of TERT.
-
Imipramine Workflows for Autophagy and Apoptosis
2026-08-15
A practical research guide to using Imipramine across glioma autophagy, leukemia apoptosis, neuroprotection, and immune-response studies. It translates ceramide-centered lipidomics into controlled assay designs while emphasizing dose finding, orthogonal readouts, compound handling, and cross-domain limitations.